Drug intelligence / Profile preview

Morphomer a-syn

Development stage: Preclinical
Lead developer: AC Immune
Modality: Small Molecules
Administration: Oral

Overview

Morphomer a-syn (also known as ACI-5755) is an oral, brain-penetrant small molecule alpha-synuclein aggregation inhibitor being developed by AC Immune for the treatment of Parkinson's disease and other synucleinopathies. Discovered using AC Immune's proprietary Morphomer technology platform, the compound is designed to selectively bind to pathological, misfolded forms of alpha-synuclein with high affinity, preventing their aggregation and seeding, and reducing neurotoxicity. It is currently in preclinical development.

Other names: Morphomer alpha-synuclein

Targets

aggregated α-syn (Alpha-synuclein (α-syn))

Beyond the preview

Go deeper on Morphomer a-syn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morphomer a-syn.

Explore the full profile